Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mass Screening | 6 | 2025 | 700 | 0.600 |
Why?
|
| Critical Pathways | 2 | 2024 | 31 | 0.390 |
Why?
|
| Colorectal Neoplasms | 3 | 2004 | 290 | 0.340 |
Why?
|
| Sigmoidoscopy | 2 | 2004 | 16 | 0.260 |
Why?
|
| Primary Health Care | 4 | 2025 | 726 | 0.240 |
Why?
|
| Videotape Recording | 1 | 2004 | 46 | 0.210 |
Why?
|
| Electronic Health Records | 2 | 2026 | 398 | 0.210 |
Why?
|
| Machine Learning | 1 | 2026 | 197 | 0.200 |
Why?
|
| Outpatients | 1 | 2025 | 143 | 0.200 |
Why?
|
| Wearable Electronic Devices | 1 | 2024 | 79 | 0.200 |
Why?
|
| Patient Education as Topic | 2 | 2004 | 489 | 0.190 |
Why?
|
| Suicide | 1 | 2024 | 148 | 0.180 |
Why?
|
| Dementia | 1 | 2026 | 290 | 0.180 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 360 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2024 | 763 | 0.150 |
Why?
|
| Guideline Adherence | 2 | 2003 | 310 | 0.150 |
Why?
|
| Warfarin | 1 | 1999 | 125 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 113 | 0.130 |
Why?
|
| Exercise | 1 | 2024 | 970 | 0.130 |
Why?
|
| Obesity | 1 | 2024 | 1281 | 0.120 |
Why?
|
| Anticoagulants | 1 | 1999 | 529 | 0.110 |
Why?
|
| Prothrombin Time | 1 | 1989 | 6 | 0.080 |
Why?
|
| Blood Coagulation Tests | 1 | 1989 | 6 | 0.080 |
Why?
|
| Partial Thromboplastin Time | 1 | 1989 | 9 | 0.080 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1989 | 51 | 0.070 |
Why?
|
| Male | 9 | 2026 | 31410 | 0.070 |
Why?
|
| Female | 8 | 2026 | 34424 | 0.070 |
Why?
|
| Humans | 15 | 2026 | 65843 | 0.070 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 1988 | 13 | 0.070 |
Why?
|
| Sarcoma, Kaposi | 1 | 1988 | 17 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2026 | 2116 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 1988 | 84 | 0.070 |
Why?
|
| Prednisone | 1 | 1988 | 83 | 0.070 |
Why?
|
| Aged | 5 | 2026 | 15147 | 0.060 |
Why?
|
| Risk Factors | 3 | 2026 | 5475 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2026 | 5682 | 0.060 |
Why?
|
| Computers, Handheld | 1 | 2025 | 37 | 0.050 |
Why?
|
| Industry | 1 | 1985 | 59 | 0.050 |
Why?
|
| Molecular Biology | 1 | 1985 | 65 | 0.050 |
Why?
|
| Adult | 5 | 2024 | 17579 | 0.050 |
Why?
|
| Universities | 1 | 1985 | 169 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 1985 | 137 | 0.050 |
Why?
|
| Middle Aged | 5 | 2024 | 18501 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 1988 | 411 | 0.050 |
Why?
|
| Suicidal Ideation | 1 | 2024 | 133 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2026 | 1148 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2025 | 318 | 0.050 |
Why?
|
| Physicians, Family | 1 | 2003 | 75 | 0.050 |
Why?
|
| Hospitals, Teaching | 2 | 1995 | 105 | 0.050 |
Why?
|
| Biomedical Research | 1 | 1985 | 263 | 0.040 |
Why?
|
| Liver Glycogen | 1 | 2001 | 2 | 0.040 |
Why?
|
| Iron Chelating Agents | 1 | 2001 | 7 | 0.040 |
Why?
|
| Hexoses | 1 | 2001 | 3 | 0.040 |
Why?
|
| Barium Sulfate | 1 | 2001 | 17 | 0.040 |
Why?
|
| Enema | 1 | 2001 | 14 | 0.040 |
Why?
|
| Occult Blood | 1 | 2001 | 19 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2025 | 2651 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2001 | 97 | 0.040 |
Why?
|
| Contraindications | 1 | 1999 | 52 | 0.040 |
Why?
|
| Dexfenfluramine | 1 | 1998 | 5 | 0.040 |
Why?
|
| Appetite Depressants | 1 | 1998 | 6 | 0.040 |
Why?
|
| Fenfluramine | 1 | 1998 | 5 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2003 | 741 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 1999 | 296 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2003 | 731 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 634 | 0.030 |
Why?
|
| Heart Valve Diseases | 1 | 1998 | 94 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2003 | 712 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 1999 | 203 | 0.030 |
Why?
|
| Depression | 1 | 2024 | 910 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 859 | 0.030 |
Why?
|
| Liver | 1 | 2001 | 875 | 0.030 |
Why?
|
| Hospital-Physician Relations | 1 | 1995 | 3 | 0.030 |
Why?
|
| Decision Making, Organizational | 1 | 1995 | 25 | 0.030 |
Why?
|
| Echocardiography | 1 | 1998 | 513 | 0.030 |
Why?
|
| Total Quality Management | 1 | 1995 | 56 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 1995 | 85 | 0.030 |
Why?
|
| Massachusetts | 1 | 2001 | 2158 | 0.030 |
Why?
|
| Health Services Research | 1 | 1995 | 265 | 0.030 |
Why?
|
| Pennsylvania | 1 | 1989 | 66 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 1998 | 2500 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1989 | 106 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1988 | 37 | 0.020 |
Why?
|
| Information Dissemination | 1 | 1985 | 114 | 0.010 |
Why?
|
| Research | 1 | 1985 | 195 | 0.010 |
Why?
|
| Culture | 1 | 2003 | 82 | 0.010 |
Why?
|
| Postprandial Period | 1 | 2001 | 20 | 0.010 |
Why?
|
| Placebos | 1 | 2001 | 73 | 0.010 |
Why?
|
| Sucrose | 1 | 2001 | 30 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 163 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2001 | 371 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2001 | 747 | 0.010 |
Why?
|
| Heart Valves | 1 | 1998 | 26 | 0.010 |
Why?
|
| Medicare | 1 | 2003 | 629 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1998 | 142 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1998 | 213 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2003 | 505 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 770 | 0.010 |
Why?
|
| Orthopedic Nursing | 1 | 1995 | 1 | 0.010 |
Why?
|
| Clinical Nursing Research | 1 | 1995 | 3 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 1995 | 14 | 0.010 |
Why?
|
| New York City | 1 | 1995 | 96 | 0.010 |
Why?
|
| New York | 1 | 1995 | 144 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 1995 | 42 | 0.010 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 1995 | 40 | 0.010 |
Why?
|
| Case Management | 1 | 1995 | 53 | 0.010 |
Why?
|
| Diffusion of Innovation | 1 | 1995 | 67 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 1995 | 100 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 1995 | 159 | 0.010 |
Why?
|
| Disease Progression | 1 | 1998 | 1229 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1995 | 491 | 0.010 |
Why?
|
| Program Evaluation | 1 | 1995 | 501 | 0.010 |
Why?
|
| Emergency Medicine | 1 | 1995 | 195 | 0.010 |
Why?
|
| United States | 1 | 1985 | 8189 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1995 | 1438 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1998 | 6957 | 0.000 |
Why?
|